Pipeline
Pipeline Programs
EB-003
Prescription Model
Highlights
-
Moderate dose
-
Prescription model
-
Taken regularly
-
Minimal side effects and reduced hallucinations
-
Available to a large patient population
Enveric is advancing its EB-003, expected to offer a first-in-class, new approach to the treatment of difficult-to-address anxiety, depression and other disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient.
Synopsis of Target Benefits
- Reduced hallucination profile
- Improved cardiac safety
- Orally bioavailable, chronic administration
- Treatment in clinic not required
- Drug intended to be prescribed for regular maintenance and taken at times and in settings more convenient to patient